Instituto Grifols, S.A.

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Instituto Grifols, S.A. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 7 completed top decile by trial count

Instituto Grifols, S.A.: 10 sponsored US clinical trials, 1 recruiting.

Instituto Grifols, S.A. sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 1 trials.

Top-decile sponsor footprint

Instituto Grifols, S.A. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

NCT07264517
TERMINATED Phase 3

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
COMPLETED Phase 3

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

NCT03461406
TERMINATED Phase 2

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

NCT02176863
COMPLETED Phase 2

Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

NCT02014402
COMPLETED Phase 3

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

NCT01754480
COMPLETED Phase 3

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

NCT01662856
COMPLETED Phase 2

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
COMPLETED Phase 4

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569
COMPLETED Phase 2

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

NCT00742417

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 4
Phase 4 1

Therapeutic Areas

Dry Eye Disease 1
Alzheimers Disease 1

What is open in the Instituto Grifols, S.A. pipeline

1 recruiting of 10 indexed (10% open); 7 completed (70%).

Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Dry Eye Disease (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Instituto Grifols, S.A.: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Instituto Grifols, S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Instituto Grifols, S.A.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Instituto Grifols, S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Instituto Grifols, S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Instituto Grifols, S.A. page

10 registered trials is a research-attention snapshot, not an endorsement of Instituto Grifols, S.A. or any single study.

  • 1 of Instituto Grifols, S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dry Eye Disease is the condition Instituto Grifols, S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Instituto Grifols, S.A. pipeline card: 10 registered trials from official public datasets.Report a data error.